Key result
Periprocedural bleeding after TAVI did not impact mid-term survival (OR 0.9; 95% CI 0.47-1.7; P=0.78), despite being associated with increased 30-day mortality.
Why the study?
Does periprocedural bleeding after TAVI increase the risk of mid-term all-cause death in patients undergoing TAVI?
Population
714 consecutive patients who underwent transcatheter aortic valve implantation, average age 81.9 ± 5.8 years.
Comparison
Life-threatening or major bleeding after TAVI vs No life-threatening or major bleeding
Design
Cohort
Follow-up
mid-term
Authors
Loading...
Periprocedural bleeding after TAVI was associated with higher 30-day but not mid-term mortality; leaves open whether mitigation strategies improve prognosis.
Cohort (n=714)
Yes
Does periprocedural bleeding after TAVI increase the risk of mid-term all-cause death in patients undergoing TAVI?
Odds Ratio: 0.9 (95% CI 0.47–1.7)
p-value: p=0.78
Periprocedural bleeding after TAVI is associated with increased 30-day mortality but does not significantly impact mid-term survival.
Moretti et al. (2014) conducted a cohort in Patients undergoing transcatheter aortic valve implantation (TAVI) (n=714). Periprocedural bleeding (life-threatening or major) vs. No significant bleeding was evaluated on Mid-term all-cause death (OR 0.9, 95% CI 0.47-1.7, p=0.78). Periprocedural bleeding after TAVI did not impact mid-term survival (OR 0.9; 95% CI 0.47-1.7; P=0.78), despite being associated with increased 30-day mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: